Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol

Chunhoo Cheon, Sohyeon Kang, Youme Ko, Mia Kim, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko, Chunhoo Cheon, Sohyeon Kang, Youme Ko, Mia Kim, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko

Abstract

Introduction: Cancer is a major health problem worldwide and the leading cause of death in many countries. The number of patients with cancer and socioeconomic costs of cancer continues to increase. SH003 is a novel herbal medicine consisting of Astragalus membranaceus, Angelica gigas and Trichosanthes Kirilowii Maximowicz. Preclinical studies have shown that SH003 has therapeutic anticancer effects. The aim of this study is to determine the maximum tolerated dose of SH003 in patients with solid cancers.

Methods and analysis: This study is an open-label, dose-escalation trial evaluating the safety and tolerability of SH003. The traditional 3+3 dose-escalation design will be implemented. Patients with solid cancers will be recruited. According to dose level, the patients will receive one to four tablets of SH003, three times a day for 3 weeks. Toxicity will be evaluated using common terminology criteria for adverse events (CTCAE). Dose-limiting toxicities are defined as grade 3 or higher adverse events based on CTCAE. The maximum tolerated dose will be determined by the highest dose at which no more than one of six patients experiences dose-limiting toxicity.

Ethics and dissemination: This study has been approved by the institutional review board of the Ajou University Hospital (reference AJIRB-MED-CT1-16-311). The results of this study will be disseminated through a scientific journal and a conference.

Trial registration number: NCT03081819; Pre-results.

Keywords: clinical trials; complementary medicine; herbal medicine; oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow chart. DLT, dose-limiting toxicity.

References

    1. World Health Organization. Cancer, fact sheet: World Health Organization, 2017. Updated Feb 2017.
    1. World Health Organization. World cancer report 2014. Lyon: International Agency for Research on Cancer, 2014.
    1. National Cancer Center. National cancer information center. 2017. (accessed July 2017).
    1. Hyun KR, Lee SM. Analysis of socioeconomic costs of five major diseases. Health insurance & policy 2014;13:91–107.
    1. Auyeung KK, Han QB, Ko JK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. Am J Chin Med 2016;44:1–22. 10.1142/S0192415X16500014
    1. Choi HS, Cho SG, Kim MK, et al. . Decursin in Angelica gigas Nakai (AGN) Enhances doxorubicin chemosensitivity in NCI/ADR-RES Ovarian cancer cells via inhibition of P-glycoprotein expression. Phytother Res 2016;30:2020–6. 10.1002/ptr.5708
    1. Li J, Li H, Zhang Z, et al. . The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3. Biol Res 2016;49:21 10.1186/s40659-016-0081-8
    1. National College of Korean Medicine Publication Committee on Joint Textbook. Herbology. Seoul, Korea: Younglimsa, 2016.
    1. Choi YK, Cho SG, Choi YJ, et al. . SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes. Oncotarget 2017;8:88386–400. 10.18632/oncotarget.11393
    1. Choi YK, Cho SG, Woo SM, et al. . Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm 2014;2014:1–11. 10.1155/2014/492173
    1. Choi HS, Kim MK, Lee K, et al. . SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. Oncotarget 2016;7:32969–79. 10.18632/oncotarget.8808
    1. Choi YJ, Choi YK, Lee KM, et al. . SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med 2016;16:507 10.1186/s12906-016-1490-5
    1. Woo SM, Kim AJ, Choi YK, et al. . Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer. Phytother Res 2016;30:1817–23. 10.1002/ptr.5687
    1. Storer BE. An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med 2001;20:2399–408. 10.1002/sim.903
    1. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, MD, USA: Food and Drug Administration, 2005.
    1. U.S.Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.03: National Institutes of Health National Cancer Institute. 2010.
    1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidnece, mortality and prevalence worldwide in 2012: World Health Organization, 2012.
    1. National Cancer Center. Cancer facts & figures 2014: Ministry of Health & Welfare, 2014.
    1. Ministry of Food and Drug Safety. MFDS, results of the investigational new drug approval status 2016: Ministry of Food and Drug Safety, 2017.
    1. Choi HS, Cho SG, Kim MK, et al. . SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. Mol Cell Biochem 2017;426(1-2):1–8. 10.1007/s11010-016-2875-y
    1. Kim HY, Kim J, Ha Thi HT, et al. . Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model. BMC Complement Altern Med 2016;16:473 10.1186/s12906-016-1447-8
    1. Choi BY, Joo JC, Lee YK, et al. . Anti-cancer effect of scutellaria baicalensis in combination with cisplatin in human ovarian cancer cell. BMC Complement Altern Med 2017;17:277 10.1186/s12906-017-1776-2
    1. Lee SI, Bae JA, Ko YS, et al. . Geijigajakyak decoction inhibits the motility and tumorigenesis of colorectal cancer cells. BMC Complement Altern Med 2016;16:288 10.1186/s12906-016-1281-z
    1. Jeong JS, Ryu BH, Kim JS, et al. . Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther 2010;9:331–8. 10.1177/1534735410383170
    1. Liu WJ Traditional herbal medicine research methods: identification, analysis, bioassay, and pharmaceutical and clinical studies: Wiley, 2011.
    1. Ministry of Food and Drug Safety. The Korean pharmacopoeia eleventh edition, ministry of food and drug safety. Seoul, Korea, 2017.
    1. Lee S, Lee YS, Jung SH, et al. . Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res 2003;26:727–30. 10.1007/BF02976682
    1. Ma X, Tu P, Chen Y, et al. . Preparative isolation and purification of two isoflavones from Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao by high-speed counter-current chromatography. J Chromatogr A 2003;992(1-2):193–7. 10.1016/S0021-9673(03)00315-7
    1. Wu J, Ke X, Ma N, et al. . Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1α/VEGF signaling pathway. Drug Des Devel Ther 2016;10:3071–81. 10.2147/DDDT.S114022
    1. Chen J, Hou R, Zhang X, et al. . Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One 2014;9:e91245 10.1371/journal.pone.0091245
    1. Wu XY, Xu H, Wu ZF, et al. . Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget 2015;6:44563–78. 10.18632/oncotarget.6310
    1. Kim KM, Kim MJ, Kang JS. Absorption, distribution, metabolism, and excretion of decursin and decursinol angelate from Angelica gigas Nakai. J Microbiol Biotechnol 2009;19:1569–72. 10.4014/jmb.0905.05028
    1. Zhang J, Li L, Hale TW, et al. . Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. PLoS One 2015;10:e0114992 10.1371/journal.pone.0114992

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅